Dystrogen Therapeutics has developed novel chimeric cell therapy for treating patients with Sarcopenia – progressive, age related, deterioration and wasting of skeletal muscles. Our chimeric cells are created via ex-vivo fusion of myoblast cells from multiple healthy donors and MSCs. This created a unique cell with a favorable HLA haplotype resulting in an attenuated immune response and better cell engraftment. These myoblast-like chimeric cells produce a number of growth factors which promote skeletal and cardiac muscle function. Our therapy can potentially mitigate the effects of sarcopenia, enhance muscle strength and slow the loss of skeletal muscle mass.